Company Focus
BioNTech
Latest BioNTech News
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to BioNTech
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello today posted financial results for the third quarter of 2024, which pleased investors. 14 November 2024
Pharmaceutical
Gilead Sciences has announced new data from its pivotal Phase III PURPOSE 2 trial providing further details on the efficacy, safety and tolerability of twice-yearly lenacapavir for HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people. 13 November 2024
Biotechnology
Sino-American firm Insilico Medicine has shown the potential not just of its pipeline and lead candidate by presenting impressive Phase IIa data this week, but also of its in-silico drug discovery model and the wider artificial intelligence (AI) field. 13 November 2024
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug (IND) application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates, US vaccines developer Novavax revealed yesterday. 12 November 2024
Biotechnology
Norwegian clinical-stage biotech Nykode Therapeutics revealed that it has received notification from Genentech, a US subsidiary of Roche, of its decision to terminate the collaboration and licensing agreement for Nykode’s VB10.NEO cancer vaccine program. 12 November 2024
Biotechnology
RAPT Therapeutics has announced the termination of its zelnecirnon program following regulatory concerns around safety. 12 November 2024
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello has entered into a strategic license agreement with US-based ARS Pharmaceuticals. 11 November 2024
Pharmaceutical
In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. 11 November 2024
Pharmaceutical
Pfizer has announced plans to invest $1 billion in China by 2030, targeting accelerated innovation, diagnostics improvements, and support for the local biotechnology sector. 8 November 2024
Latest In Brief for BioNTech
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Latest Relevant Ones To Watch News
Taiwan-based REGiMMUNE, a biopharma creating immunotherapies through the power of regulatory T cells (Tregs), and France-based Kiji Therapeutics, a specialist in induced pluripotent stem cells-mesenchymal stem cells (IPSC-MSC) engineered cell therapies for inflammatory diseases, are to merge. 18 October 2024
23 September 2024
19 September 2024
16 September 2024
8 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze